利司鲁肽治疗2型糖尿病的系统评价

发布时间：2018-08-20 17:36

【摘要】：目的:系统评价新型GLP-1受体激动剂利司鲁肽治疗2型糖尿病的疗效与安全性。方法:电子检索中英文数据库中有关利司鲁肽治疗2型糖尿病的随机临床试验(RCT),时限至2016年5月;2位研究者独立评阅文献,并筛选及予以质量评价;采用RevMan 5.0软件对各效应指标进行Meta分析。结果:纳入7篇RCT,文献质量评价均属低偏倚风险,2型糖尿病患者共计2 089例,其中试验组(利司鲁肽治疗)1 128例,对照组(安慰剂)961例,Meta分析结果显示,于治疗周期末,2组HbA1c水平、HbA1c达标率(≤6.5%)有统计学差异(P0.05),FPG水平变化无统计学差异(P0.05),恶心、呕吐、胃肠功能紊乱、低血糖反应及因不良事件(AE)退出治疗的发生率有统计学差异(P0.05),腹泻、头痛、头晕、鼻咽炎及SAE发生率无统计学差异(P0.05)。结论:利司鲁肽对2型糖尿病患者血糖水平有较好控制作用,但其不良反应发生率仍有较大差异,尚需更多大样本、多中心随机临床试验予以证实。
[Abstract]:Objective: to evaluate the efficacy and safety of a novel GLP-1 receptor agonist, riselutin, in the treatment of type 2 diabetes mellitus. Methods: the (RCT), time limit of the randomized clinical trial of Lisrop for type 2 diabetes mellitus was searched electronically in Chinese and English database, and two researchers independently reviewed the literature until May 2016, and selected and evaluated the quality of the literature. RevMan 5.0 software was used to analyze each effect index by Meta. Results: a total of 2 089 patients with type 2 diabetes mellitus with low bias risk were included in 7 RCTs, including 1 128 patients in the trial group (treated with risurutin) and 961 patients in the control group (placebo). At the end of the treatment cycle, there was no significant difference in the HbA1c level (鈮，

本文编号：2194447